Cure CML Consortium Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03610971
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

H. Jean Khoury Cure CML Consortium